Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDK4/6 inhibitor + ET in HR+/HER2- advanced breast cancer
NCT05295043Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2022
- Primary completion
- Jan 2024
01
Overview
Open-label trial in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05295043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295043.